(29 December 2015 - Hong Kong) YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “Company”, stock code: 01558.HK), commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited (“SEHK”) today.
      Commenting on the positive reaction of the market, Mr. Tang Xinfa, chairman of the Company said, “Our company focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases in the PRC. We were ranked amongst the top 4 pharmaceutical manufacturing companies in the anti-influenza virus product market in the PRC in terms of sales revenue last year, and we were ranked No. 1 in the oseltamivir phosphate product category in terms of sales revenue in each of 2013 and 2014. We will continue to maintain our strength and enhance our position in the anti-influenza virus therapeutic area while expanding our product portfolio in strategically selected therapeutic areas. Being successfully listed on the Hong Kong Stock Exchange, we have opened up new horizons for future developments. As we start our new journey today, we will continuously forge ahead and endeavor to become a leading pharmaceutical company and deliver ideal returns for our shareholders and investors.”

About YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

      HEC Pharm is a PRC pharmaceutical manufacturing company that focuses on the development, manufacturing and sale of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases and cardiovascular diseases. According to PICO, the Company’s anti-influenza virus product, Kewei (oseltamivir phosphate) accounted for 0.5%, 3.8% and 8.2% of the anti-influenza virus product market (based on retail prices, excluding traditional Chinese medicine products) in the PRC and accounted for 17.9%, 71.9% and 84.1% of the oseltamivir phosphate product market in the PRC in 2012, 2013 and 2014 respectively. According to PICO, the Company was ranked amongst the top 4 pharmaceutical manufacturing companies in 2014 in the anti-influenza virus product market in the PRC in terms of sales revenue, and was ranked No. 1 in the oseltamivir phosphate product category in the PRC in terms of sales revenue in each of 2013 and 2014. Going forward, the Company intends not only to continue to maintain its strength in the anti-influenza virus therapeutic area but also to expand its product portfolio to cover other therapeutic areas which it believes have substantial growth potential.